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Abstract
Background: Lung cancer is known to metastasize to the pancreas with several case reports
found in the literature, however, most patients are at an advanced stage and receive palliative
treatment.
Case presentation: We describe the case of a 56 year old male patient who presented with a
picture of obstructive jaundice. Investigations revealed an obstructing lesion in the pancreas and a
further lesion in the lung with benign appearances. The patient underwent a pancreatectomy and,
unexpectedly, the histology of the resected specimen demonstrated metastatic adenocarcinoma of
bronchogenic origin. He was referred to a cardiothoracic team who proceeded to resect the
patient's thoracic lesion before administration of adjuvant chemotherapy. The patient was reviewed
18 months post operatively and remains symptom free with no clinical or radiological evidence of
recurrence. We were unable to identify any previous case reports (of lung adenocarcinoma) with
such a presentation which were ultimately treated with resection of both lesions.
Conclusion: Similar situations are bound to arise again in the future and we believe that this
report could demonstrate that there is a case for aggressive surgical management in a highly
selected group of patients: those with NSCLC and a synchronous solitary pancreatic deposit.
Background
That a variety of malignant tumours can metastasise to the
pancreas is well documented. Several case reports have
reported patients with lung cancer whose clinical presen-
tation was that of obstructive jaundice [1].
Most patients presenting in this manner are at an
advanced stage with widespread disease, and are usually
managed symptomatically. This generally involves pallia-
tive chemotherapy and/or radiotherapy coupled with
other measures to relieve the biliary obstruction such as
biliary stent insertion. In the few cases where operative
intervention is considered, it is usually limited to a biliary
bypass to relieve the jaundice.
We describe an unusual presentation where an adenocar-
cinoma of the lung with a synchronous solitary metastatic
deposit in the pancreas (not visible on CT) was treated
with operative resection of both lesions. The uniqueness
of this case is enhanced by the fact that both lesions were
identified preoperatively although their nature was not.
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Case presentation
A 56 year old male lawyer presented to his local hospital
complaining of a recent change in his urine colour (to
bright orange) and general malaise. The patient suffered
from moderate bronchiectasis and asthma for which he
took inhalers (fluticasone propionate, salmeterol and
ipratropium bromide). He was also known to be hyper-
tensive (controlled on diltiazem) and suffered from severe
eczema. He had never been a smoker but his daily con-
sumption of alcohol amounted to 1.5 bottles of wine.
Initial workup revealed deranged liver function tests and
relevant tumour markers were raised (Ca 19-9 181 kU/l,
CEA 25.8 μg/l). A subsequent abdominal ultrasound
showed biliary dilatation to the level of the pancreas. This
was confirmed on an MRCP. However CT (64 slice fine
cut spiral pancreas protocol CT) and MRI examinations
failed to reveal any pancreatic mass (figure 1). An ERCP
which followed confirmed the lower CBD stricture with
features of external compression and a plastic biliary stent
was inserted.
The patient was then referred to our unit for further treat-
ment. The working diagnosis at this stage was a pancreatic
tumour and the patient underwent staging with a view to
a pancreatic resection. Unusually, as part of the initial
workup, the patient had had a CT of his thorax, showing
a right lung lesion, thought to be benign, on a background
of known chronic respiratory disease (figure 2). A FDG-
CT scan abdomen Figure 1
CT scan abdomen. Stent visible in bile duct.
CT scan chest Figure 2
CT scan chest. Lesion in the right lung.
FDG PET scan Figure 3
FDG PET scan. Lesion in the right lung.World Journal of Surgical Oncology 2008, 6:120 http://www.wjso.com/content/6/1/120
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PET scan was performed to delineate the lung lesion fur-
ther (figure 3). This scan was reported as positive, thus
raising the possibility of:
• A lung primary with pancreatic metastasis
￿ Synchronous pancreatic and lung primaries
￿ A pancreatic primary with lung metastasis
CT guided biopsy of the lung lesion was performed, the
histology of which showed reactive changes but no evi-
dence of malignancy. As such and in view of the patient's
background of respiratory disease the PET scan was inter-
preted as demonstrating reactive changes. Given the pres-
entation, tumour markers, imaging appearances and
biopsy results the working diagnosis remained that of a
pancreatic cancer with no evidence of metastatic disease.
The patient proceeded to a pylorus preserving pancreati-
coduodenectomy (PPPD). There was no evidence of intra-
abdominal spread at laparotomy. The head of the pan-
creas contained a palpable mass. This was resected in rou-
tine fashion. The histology of the resected specimen was a
single poorly differentiated adenocarcinoma (figure 4)
(11 mm in maximum dimension) staining strongly posi-
tive to TTF-1 and CK7 (figure 5), and negative staining for
CK20 and PSA. The tumour did not approach any of the
resection margins or surfaces. Also, none of the surround-
ing 16 lymph nodes had any evidence of disease.
In view of the reported immunohistochemical profile,
coupled with the identification of a lung lesion, the
tumour was interpreted as metastatic adenocarcinoma of
bronchial origin rather than as a primary pancreatic
lesion. As a result the patient was referred to a thoracic sur-
geon for consideration of removal of the lung lesion. Six
weeks later the patient underwent a mini thoracotomy
where a 2 × 3 cm lesion was identified in the medial seg-
ment of the upper lobe of the right lung. The segment was
removed along with hilar and mediastinal lymph nodes
for staging. Histology of this specimen reported a lung
adenocarcinoma with complete excision and no lymph
node involvement.
Three weeks after his lung resection the patient was started
on adjuvant chemotherapy with gemcitabine and carbo-
platin. This regime was continued for 6 months. The
patient was seen eighteen months from presentation.
Clinically he remained symptom free and a follow-up CT
of his chest and abdomen revealed no evidence of recur-
rence.
Discussion
Pancreatic cancer is one of the leading causes of cancer
deaths ranking 4th in the US and 6th in Europe [2]. How-
ever, little attention is devoted to secondary deposits of
other tumours to the pancreas. Retrospective studies on
pancreatectomy procedures have reported that metastatic
disease represents merely 3% or so of resected malignant
pancreatic masses [3,4]. As such they are often mistaken as
pancreatic primaries and only recognised for what they
truly are in retrospect on histological examination [5].
Some 98% of patients with a malignant process who
present with obstructive jaundice will do so as a result of
a primary pancreatic cancer [6]. On the other hand,
autopsy statistics suggest that the pancreas is a more fre-
High magnification view of lesion resected from the pancreas  (haematoxylin and eosin) Figure 4
High magnification view of lesion resected from the 
pancreas (haematoxylin and eosin).
High magnification view of lesion resected from the pancreas  (immunohistochemical staining with TTF-1) Figure 5
High magnification view of lesion resected from the 
pancreas (immunohistochemical staining with TTF-
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quent site for metastatic disease, albeit on a subclinical
scale. The incidence of secondary pancreatic tumours is up
to 16% of autopsy studies [7], with a wide variation of pri-
mary cancers responsible. Patients who present with a
clinical picture which relates directly to disease in the pan-
creas at presentation will tend to do so with the symptoms
of obstructive jaundice or pancreatitis [8]. More often
than not these patients prove to have advanced disease
which is only amenable to palliative treatment.
Lung cancer metastasizes to many sites, but most fre-
quently to bone, the liver and the adrenal glands [9,10].
Approximately one third of patients will present with
symptoms relating to extra thoracic spread [10]. The pan-
creas is considered to be an infrequent target to which
lung cancer will metastasize to. Figures are reported in the
range of 0–12% [11-13]. The majority of those which do
are of SCLC histological subtype [14]. Rarer still, at pres-
entation, is for lung cancer to present with a clinical pic-
ture of jaundice due to synchronous metastatic
adenocarcinoma [1]. In those cases where it does, this is
more likely to be due to widespread hepatic disease than
to extrahepatic biliary obstruction [15]. A larger subgroup
of patients with lung cancer will develop a metachronous
pancreatic metastasis, which will usually be identified on
follow-up investigations. One recent case report pub-
lished in March 2008 reports the first case of lung adeno-
carcinoma with a metachronous isolated deposit in the
pancreas and no evidence of other disease. This case was
treated with biliary stenting and palliative chemotherapy
[16].
Of secondary deposits discovered in the pancreas, lung
cancer makes up (along with renal cell carcinoma, breast
and gastric cancer) a high percentage (table 1) [7,17-36].
Indicative published figures are 14.2% (49 of 311 second-
ary tumours) [7], 17.0% (18 of 108)[18] and 18.2% (4 of
22) [17]. The large majority of cancer patients with meta-
static disease to the pancreas are treated with palliative
intent as patients usually present with widespread disease.
Where surgery is contemplated, it is usually limited to
bypass procedures in patients with obstructive jaundice.
There have been reports where patients with this presenta-
tion have undergone more major procedures such as pan-
creatic resection[37], but this has tended to be in
ignorance of the fact that the aetiology of the obstruction
was of metastatic origin, as was in our case. There are sev-
eral publications advocating the consideration of a pan-
creatic resection in selected cases. One of these is a
literature review by Minni et al, where 333 cases with sec-
ondary deposits in the pancreas were reviewed. Of these,
234 had treatment information of which 150 (64.1%)
underwent pancreatic resections [3]. More than 25 differ-
ent histologic types are reported 45.0% of which were
renal cell, 14.7% lung, 7.5% breast and 6.6% colonic car-
cinomas. In a series of twelve patients with a variety of dif-
ferent metastatic tumours to the pancreas, Le Borgne et al
[38], suggest that a more aggressive surgical approach
should be considered, especially in patients with meta-
chronous ampullary and pancreatic deposits from renal
cell carcinomas, sarcomas and carcinoid tumours. They
reported 35% survival rate at 2 years and 17% at 4 years.
Stage IV NSCLC has a poor prognosis. Median survival
with best supportive care is reported as 3.6 months (range,
2.4 to 4.9 months) whilst platinum based chemotherapy
regimes increase this statistic to 6.5 months (range, 4.7 to
8.5 months). This patient is alive and disease free 18
months following presentation. It is accepted practice
today to consider selected patients with solitary intracra-
nial deposits for resection [39-41]. Also it has been sug-
gested repeatedly that a survival benefit may be achieved
by surgical treatment of solitary extracranial spread of
NSCLC [42-46]. The experience and information availa-
ble for the surgical treatment of metastatic disease from
the lung exclusively to the pancreas is very limited and few
guidelines are available on the appropriate management
of such cases. Most series describe treatment which, from
the outset had a palliative intent. Hiotis et al [47], how-
ever, report three cases of patients with metachronous
(information from personal correspondence with author)
NSCLC metastatic disease to the pancreas who underwent
Table 1: Summary of world literature on pancreatic metastases 
from lung cancer
Lung cancer histology subtype
Small Cell Lung Cancer (22)
Adenocarcinoma1 (4)
Large Cell (2)
Squamous Cell (2)
Anaplastic bronchial (1)
'Lung Cancer'2 (4)
Presenting symptoms
Obstructive Jaundice1 (15)
Acute Pancreatitis (13)
No Symptoms3 (5)
Gastrointestinal bleed (1)
Not Available (1)
Treatment Received4
Palliative Chemotherapy (13)
Biliary stent (8)
Palliative Operation (4)
Best Supportive Care (7)
Pancreatic Resection (6)
Adjuvant Chemotherapy (2)
Exploratory laparotomy (1)
Includes our case. 2 No further information from authors 3 Includes 
patients who were identified on surveillance. 4 Some patients received 
more than one treatment.
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pancreatectomies with curative intent. All patients devel-
oped recurrence.
Conclusion
In the majority of cancers, synchronous presentation gen-
erally carries a worse prognosis than a metachronous one.
Our case is an example of a synchronous metastatic
deposit resected (albeit) inadvertently. However, resec-
tion of both lesions has led to long-term disease-free sur-
vival. Therefore we believe that this report demonstrates
that in selected cases consideration should be given not
just to palliation but to potentially curative surgery
whether it be synchronous or more likely metachronous
presentation of metastatic lung cancer to the pancreas.
This is very different from what has been described previ-
ously where very few operations with curative intent have
been carried out, in particular on patients with NSCLC.
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Cholangiopancreatography; ERCP: Endoscopic Retro-
grade Cholangiopancreatography; CBD: Common Bile
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